BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 19, 2018

View Archived Issues

Brain sleepiness signature, links to memory identified

Read More

FDA issues complete response letter for Duobrii lotion

Read More

Amgen initiates phase I trial of AMG-119 in small cell lung cancer

Read More

Safety run-in results presented from phase III ANDROMEDA study on daratumumab

Read More

Phase II results for talimogene laherparepvec plus pembrolizumab in patients with sarcoma

Read More

Forge Therapeutics LpxC inhibitor shows activity in vitro, in vivo and in combination

Read More

FDA grants fast track designation to mirvetuximab soravtansine in platinum-resistant ovarian cancer

Read More

Catalyst offers update from Cohort 6 in phase I/II trial of CB-2679d for hemophilia B

Read More

Agios initiates phase III ACTIVATE study of AG-348 in pyruvate kinase deficiency

Read More

Rhythm announces new topline clinical data for setmelanotide in rare genetic disorders of obesity

Read More

MXRA8, a drug-targetable receptor for chikunguya and other arthritogenic alphaviruses

Read More

Cognition Therapeutics initiates SPARC trial of Elayta in Alzheimer's disease

Read More

Clover initiates phase I trial of SCB-313 for malignant ascites

Read More

Sanofi completes acquisition of Ablynx

Read More

Roche and Foundation Medicine enter definitive merger agreement

Read More

FDA removes clinical hold on IGNITE DMD study of SGT-001

Read More

XMT-1522 demonstrates safety and preliminary efficacy in phase I study

Read More

Wellcome Trust grant supports Karuna's development of KarXT for schizophrenia

Read More

Xavier University of Louisiana divulges androgen receptor signaling inhibitors

Read More

Hedgehog pathway modulators patented by Development Center for Biotechnology, DCB-USA

Read More

Shanghai Institute of Materia Medica discovers BTK inhibitors

Read More

Glycogen synthase kinase 3 inhibitors patented by Bristol-Myers Squibb

Read More

FDA places clinical hold on phase I trial evaluating Ziopharm's CD19-targeted CAR T therapy

Read More

Alexion submits U.S. BLA for ALXN-1210 to treat PNH

Read More

First-in-human results reported for MK-1248 in advanced solid tumors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing